Business
Aethlon Medical Signs Collaboration Agreement with 34 Lives to Evaluate the Ability of the Hemopurifier® to Expand the Utility of Unused, Donated Kidneys for Transplant
Proof-of-Concept Studies to Support the Use of the Hemopurifier in the Ex Vivo Organ Perfusion Circuit SAN DIEGO, July 24, 2023 /PRNewswire/ -- Aethlon
About this update from Aethlon Medical, Inc.
[{"type":"text","content":"Proof-of-Concept Studies to Support the Use of the Hemopurifier in the Ex Vivo Organ Perfusion Circuit\nSAN DIEGO, July 24, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it has signed a Collaboration Agreement with 34 Lives, PBC, to investigate the use of Aethlon's proprietary Hemopurifier® technology and 34 Lives' organ evaluation and preservation system, with the goal of increasing the supply of useable donated kidneys for human transplant. Financial terms of the agreement were not disclosed.\n\"The signing of the research collaboration with 34 Lives, on the heels of our recent announcement of our interest in the organ transplant market, is a testament to Aethlon's belief that the Hemopurifier technology can potentially help expand the pool for donated kidneys available for transplant,\" stated Charles J. Fisher, Jr., M.D., Chief Executive Officer of Aethlon Medical. \"The aim of the proof-of-concept studies, to be conducted under this Agreement, is to gather compelling data to support the use of our technology in the ex vivo organ preservation system and to confirm its ability to remove harmful viruses and exosomes with injurious cargo from recovered donor organs. Aethlon has previously demonstrated the removal of multiple viruses and exosomes in vitro, utilizing a miniature version of the Hemopurifier. This process may reduce complications following transplantation of the recovered organ, including viral infection, delayed graft function and rejection by the transplant recipient. We look forward to working with 34 Lives with the goal of preserving the viability of kidneys, with the ultimate goal of saving lives.\" Chris Jaynes, Chief Executive Officer of 34 Lives added, \"The combination of the Aethlon Hemopurifier with the 34 Lives' organ preservation system may also help rescue a large percentage of the donor kidneys annually recovered for transplantation that go unused, putting them back into the donor pool with the hope of eliminating the patient waitlist for these organs.\"\nAccording to Precedence Research, the global transplantation market size is projected to hit around $33.7 billion by 2032, up from an estimated $15.1 billion in 2022, driven largely by increasing ra...